ReviewPCN reports : psychiatry and clinical neurosciences2026
Dose-dependent efficacy and safety of centanafadine in patients with attention-deficit/hyperactivity disorder: A systematic review of the latest evidence.
Review in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Centanafadine is a multimodal norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) that has been evaluated for the treatment of attention-deficit/hyperactivity disorder (ADHD) across pediatric, adolescent, and adult populations. This systematic review aimed to evaluate the efficacy, safety, and tolerability of centanafadine compared with placebo, with particular emphasis on dose-response patterns across different age groups. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to July 2026. Randomized, double-blind, placebo-controlled trials evaluating centanafadine in patients with ADHD were eligible for inclusion. The Cochrane Risk of Bias 2 (RoB 2) tool was used to assess the risk of bias. Because of differences in populations, formulations, dosing regimens, outcome measures, and reported effect estimates, findings were synthesized narratively rather than quantitatively. Four randomized trials reported in three publications, including 1845 randomized participants, were included. In children, high-dose centanafadine significantly improved attention-deficit/hyperactivity disorder rating scale, version 5 (ADHD-RS-5) scores compared with placebo (-16.3 vs. -10.8;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.